Chemotherapy Drugs Based on Solid Lipid Nanoparticles for Breast Cancer Treatment

Ashtari, Atefeh; Niazvand, Firoozeh; Khorsandi, Layasadat

doi:10.3390/medicina56120694

Cited by 5 publications

(2 citation statements)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those lying between this size range are considered to be most appropriate for cancer treatment (Smith et al, 2012;Jaiswal and Dudhe, 2015;Han et al, 2021). Nanoparticles can be classified into various types including metallic nanoparticles (Subhan, 2022), polymeric nanoparticles (Sartaj et al, 2021), solid lipid nanoparticles (Ashtari et al, 2020;Ozgenc et al, 2022), and fullerenes. The characterization of nanoparticles for drug release and drug targeting primarily depends on the evaluation of particle size and morphology (Song et al, 2020).…”

Section: Nano Technology Based-drug Delivery Systems In Breast Cancer...mentioning

confidence: 99%

“…In addition, dendrimers, lipid nanoparticles (Ashtari et al, 2020), protein nanoparticles (Lin et al, 2009), ceramic nanoparticles, viral nanoparticles, metallic nanoparticles and carbon nanotubes are few more novel drug delivery systems which have been used in cancer therapeutics (Dhman, 2017). The Nanoparticles can be modified/functionalized in many ways to enhance drug localization, reduce opsonization, enhance circulation, enhance stability and bioavailability, reduce toxicity, increase drug efficacy and potentially decrease chances of multidrug resistance (Sarika and Nirmala, 2016;Liu et al, 2020).…”

Section: Nano Technology Based-drug Delivery Systems In Breast Cancer...mentioning

confidence: 99%

See 1 more Smart Citation

A review of FDA approved drugs and their formulations for the treatment of breast cancer

et al. 2023

View full text Add to dashboard Cite

Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds. This article aims to summarize the therapeutic agents which are either being used or are currently under approval for use in the treatment or mitigation of breast cancer by the US FDA, to date. A structured search of bibliographic databases for previously published peer-reviewed research papers on registered molecules was explored and data was sorted in terms of various categories of drugs used in first line/adjuvant therapy for different stages of breast cancer. We included more than 300 peer-reviewed papers, including both research and reviews articles, in order to provide readers an useful comprehensive information. A list of 39 drugs are discussed along with their current status, dose protocols, mechanism of action, pharmacokinetics, possible side effects, and marketed formulations. Another interesting aspect of the article included focusing on novel formulations of these drugs which are currently in clinical trials or in the process of approval. This exhaustive review thus shall be a one-stop solution for researchers who are working in the areas of formulation development for these drugs.

show abstract